期刊文献+

舒张性心力衰竭患者血浆脑钠肽与超敏C反应蛋白水平及治疗前后的变化 被引量:20

Variations of the levels of plasma brain natriuretic peptide and hypersensitive C reactive protein before and after treatment in patients with diastolic heart failure
下载PDF
导出
摘要 目的探讨舒张性心力衰竭患者血浆脑钠肽(BNP)与超敏C反应蛋白(hs-CRP)水平的变化及临床意义。方法 48例(NYHY分级Ⅲ-Ⅳ级)舒张性心力衰竭患者为心衰组,其中Ⅲ级组30例,Ⅳ级组18例,分别于清晨空腹和心功能改善至Ⅰ-Ⅱ级后采血,测定血浆BNP和hs-CRP。选取30例体检健康者为对照组。结果心衰组BNP和hs-CRP均较对照组显著升高(P〈0.01),且随心衰程度加重而升高(P〈0.01)。心衰组随着心功能的改善BNP和hs-CRP明显下降,与治疗前比较差异有统计学意义(P〈0.01)。结论舒张性心力衰竭时BNP和hs-CRP均升高,且随心功能损害加剧而增高明显,治疗后均明显降低,提示BNP和hs-CRP可能是反映舒张性心力衰竭病情变化的指标。 Objective To investigate the variations of the levels of plasma brain natriuretic peptide(BNP) and hypersensitive C reactive protein(hs-CRP) in patients with diastolic heart failure(DHF).Methods 48 admitted patients with DHF were divided into class Ⅲ group(30 cases) and class Ⅳ group(18 cases) according to NYHA Functional Classification.Blood samples were taken in the morning(fasting blood) and when the heart function was improved to class Ⅰ to Ⅱ to determine the levels of plasma BNP and hs-CRP.30 healthy cases were designated as the healthy control group.Results The plasma levels of BNP and hs-CRP were higher in DHF groups than those in the healthy control group(P〈0.01).The levels of BNP and hs-CRP were higher in patients of class Ⅳ group than those of class Ⅲ group(P〈0.01).With the improvement of heart function and the evident decrease in the levels of BNP and hs-CRP in the DHF groups,the differences before and after treatment were statistically significant(P〈0.01).Conclusion The levels of BNP and hs-CRP in DHF were high and increase with the severity of DHF and could be reversed by treatment,suggesting that BNP and hs-CRP could be indicators to the variations of the status of DHF.
出处 《徐州医学院学报》 CAS 2010年第9期591-592,共2页 Acta Academiae Medicinae Xuzhou
关键词 舒张性心力衰竭 脑钠肽 超敏C反应蛋白 diastolic heart failure BNP hs-CRP
  • 相关文献

参考文献5

  • 1Owan TE,Hodge DO,Herges RM,et al.Trends in prevalence and outcome of heart failure with preserved ejection fraction[J].N Engl J Med,2006,355(3):251-259.
  • 2Bhatia RS,Tu JV,Lee DS,et al.Outcome of heart failure with preserved ejection fraction in a population-based study[J].N Engl J Med,2006,355(3):260-269.
  • 3Cowie MR,Struthers AD,Wood DA,et al.Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care[J].Lancet,1997,350(9088):1349-1353.
  • 4Hall C.Essential biochemistry and physiology of (NT-pro)BNP[J].Eur J Heart Fail,2004,6(3):257-260.
  • 5尹芝兰,赵水平.充血性心力衰竭患者血清C-反应蛋白的变化及辛伐他汀的干预作用[J].中国医师杂志,2003,5(9):1225-1226. 被引量:79

二级参考文献8

  • 1Jianhui Zhu, Quyyumi AA, Norman JE, et al, Effects of total pathogen burden on coronary artery disease risk and C - reactive protein levels[J] .Am J Cardiol,2000,85 : 140 - 146.
  • 2Wolf MG,Zasmeta G, Homykewycz S, et al. Plasma levels of C - reactive prorein after coronary stent implantation[J] .Eur Heart J,2000,21:1152 - 1158.
  • 3Lenine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure[J]. N Eng J Med, 1990,323:236- 241.
  • 4Gabay C, Kushner I. Actue - phase proteins and other systemic responses to inflammation[J]. N Eng Med, 1999,340:448 - 454.
  • 5Tataru MC,Heinrich J,Junker R,et al.C - reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris[J]. Eur Heart J,2000,21 : 1000.
  • 6Albert MA, Staggers J, Chew P, et al. Investigators. The pravastatin inflammation CRP evaluation ( PRINCE ) : rationale and design [ J ]. Am Heart J,2001,141(6) :893 - 898.
  • 7Ridker PM, Rifai N, Clearfield M, et ,ak. Measurement - C - reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events[ J], N Engl J Med, 2001,344(26) : 1959 - 1965.
  • 8Bustos C, Hemandez- Presa MA, Ortego M, et al. HMG- COA reductase inhibition by atorvastatin reduces neointial inflammation in a rabbit model of atherosclerosis[J] .J AM Coll Cardiol, 1998,32(7) :2057 - 2064.

共引文献78

同被引文献132

  • 1励伟芬,陈法余,柳茵,钟良,徐曌,刘霞,陈玉林,陈兆军,黄洪章.B型尿钠肽在心力衰竭危险分层及预后判断中的价值[J].浙江医学,2004,26(6):415-416. 被引量:13
  • 2朱卫东.洛丁新和螺内酯联用治疗老年心力衰竭的疗效[J].中国医师进修杂志,2006,29(3):47-47. 被引量:4
  • 3刘兵.老年舒张性心力衰竭18例误诊分析[J].中国医师进修杂志(内科版),2006,29(5):76-77. 被引量:1
  • 4社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量:3048
  • 5Kazik A, Wilczek K, Polonski L Management of diastolic heart failure [J]. Cardiol J,2010;17(6) :558-65.
  • 6Bhatia RS,Tu JV,Lee DS,et al. Outcome of heart failure with preserved ejection fraction in a population-based study [ J ]. N Engl J Med, 2006 ; 355(3) :260-9.
  • 7Sudoh T, Kangawa K, Minamino N,et al. A new natriuretic peptide in porcine brain [ J ]. Nature, 1988 ;332 ( 6159 ) :78-81.
  • 8McDonagh TA, Robb SD, Murdoch DR,et al. Biochemical detection of left- ventricular systolic dysfunction [ J 1. Lancet, 1998 ; 351 ( 9095 ) : 913 -6.
  • 9Barrios V, Llisterri JL, Escobar C, et al. Clinical applicability of B-type natriuretic peptide in patients with suspected heart failure in primary care in Spain : the PANAMA study [ J ]. Expert Rev Cardiovasc Ther, 2011 ;9 (5) :579-85.
  • 10Suzuki S,Takeishi Y,Niizeki T,et al. Pentraxin 3 ,a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure[ J]. Am Heart J,2008;155( 1 ) :75-81.

引证文献20

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部